FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2254594392> ?p ?o ?g. }

• W2254594392 endingPage "878" @default.
• W2254594392 startingPage "871" @default.
• W2254594392 abstract "Purpose To report the overall survival (OS) and clinical characteristics of BRAF inhibitor–naive long-term responders and survivors treated with dabrafenib plus trametinib in a phase I and II study of patients with BRAF V600 mutation–positive metastatic melanoma. Methods BRAF inhibitor–naive patients treated with dabrafenib 150 mg twice daily plus trametinib 2 mg daily (the 150/2 group) from the non–randomly assigned (part B) and randomly assigned (part C) cohorts of the study were analyzed for progression-free and OS separately. Baseline characteristics and factors on treatment were analyzed for associations with durable responses and OS. Results For BRAF inhibitor–naive patients in the 150/2 groups (n = 78), the progression-free survival at 1, 2, and 3 years was 44%, 22%, and 18%, respectively, for part B (n = 24) and 41%, 25%, and 21%, respectively, for part C (n = 54). Median OS was 27.4 months in part B and 25 months in part C. OS at 1, 2, and 3 years was 72%, 60%, and 47%, respectively, for part B and 80%, 51%, and 38%, respectively, for part C. Prolonged survival was associated with metastases in fewer than three organ sites and lower baseline lactate dehydrogenase. OS at 3 years was 62% in patients with normal baseline lactate dehydrogenase and 63% in patients with a complete response. Conclusion Dabrafenib plus trametinib results in a median OS of more than 2 years in BRAF inhibitor–naive patients with BRAF V600 mutation–positive metastatic melanoma, and approximately 20% were progression free at 3 years. Durable responses occurred in patients with good prognostic features at baseline, which may be predictive." @default.
• W2254594392 created "2016-06-24" @default.
• W2254594392 creator A5001951857 @default.
• W2254594392 creator A5002655892 @default.
• W2254594392 creator A5010628808 @default.
• W2254594392 creator A5012671311 @default.
• W2254594392 creator A5012911914 @default.
• W2254594392 creator A5015498468 @default.
• W2254594392 creator A5018322482 @default.
• W2254594392 creator A5018454677 @default.
• W2254594392 creator A5023174631 @default.
• W2254594392 creator A5028592995 @default.
• W2254594392 creator A5028976895 @default.
• W2254594392 creator A5031661938 @default.
• W2254594392 creator A5031781832 @default.
• W2254594392 creator A5037357027 @default.
• W2254594392 creator A5039187516 @default.
• W2254594392 creator A5039195753 @default.
• W2254594392 creator A5045032869 @default.
• W2254594392 creator A5047177507 @default.
• W2254594392 creator A5049243227 @default.
• W2254594392 creator A5049839632 @default.
• W2254594392 creator A5062978331 @default.
• W2254594392 creator A5069777765 @default.
• W2254594392 creator A5071577704 @default.
• W2254594392 creator A5072308451 @default.
• W2254594392 creator A5072582710 @default.
• W2254594392 creator A5075566772 @default.
• W2254594392 date "2016-03-10" @default.
• W2254594392 modified "2023-10-03" @default.
• W2254594392 title "Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib" @default.
• W2254594392 cites W1864088638 @default.
• W2254594392 cites W1965370740 @default.
• W2254594392 cites W2003402062 @default.
• W2254594392 cites W2019607817 @default.
• W2254594392 cites W2040286515 @default.
• W2254594392 cites W2096387850 @default.
• W2254594392 cites W2103557568 @default.
• W2254594392 cites W2105660237 @default.
• W2254594392 cites W2107484016 @default.
• W2254594392 cites W2111404068 @default.
• W2254594392 cites W2116978375 @default.
• W2254594392 cites W2118863192 @default.
• W2254594392 cites W2118982164 @default.
• W2254594392 cites W2121545342 @default.
• W2254594392 cites W2128035403 @default.
• W2254594392 cites W2131040858 @default.
• W2254594392 cites W2136474966 @default.
• W2254594392 cites W2152897456 @default.
• W2254594392 cites W2156078931 @default.
• W2254594392 cites W2166262263 @default.
• W2254594392 cites W2166662937 @default.
• W2254594392 cites W2190024321 @default.
• W2254594392 doi "https://doi.org/10.1200/jco.2015.62.9345" @default.
• W2254594392 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26811525" @default.
• W2254594392 hasPublicationYear "2016" @default.
• W2254594392 type Work @default.
• W2254594392 sameAs 2254594392 @default.
• W2254594392 citedByCount "249" @default.
• W2254594392 countsByYear W22545943922016 @default.
• W2254594392 countsByYear W22545943922017 @default.
• W2254594392 countsByYear W22545943922018 @default.
• W2254594392 countsByYear W22545943922019 @default.
• W2254594392 countsByYear W22545943922020 @default.
• W2254594392 countsByYear W22545943922021 @default.
• W2254594392 countsByYear W22545943922022 @default.
• W2254594392 countsByYear W22545943922023 @default.
• W2254594392 crossrefType "journal-article" @default.
• W2254594392 hasAuthorship W2254594392A5001951857 @default.
• W2254594392 hasAuthorship W2254594392A5002655892 @default.
• W2254594392 hasAuthorship W2254594392A5010628808 @default.
• W2254594392 hasAuthorship W2254594392A5012671311 @default.
• W2254594392 hasAuthorship W2254594392A5012911914 @default.
• W2254594392 hasAuthorship W2254594392A5015498468 @default.
• W2254594392 hasAuthorship W2254594392A5018322482 @default.
• W2254594392 hasAuthorship W2254594392A5018454677 @default.
• W2254594392 hasAuthorship W2254594392A5023174631 @default.
• W2254594392 hasAuthorship W2254594392A5028592995 @default.
• W2254594392 hasAuthorship W2254594392A5028976895 @default.
• W2254594392 hasAuthorship W2254594392A5031661938 @default.
• W2254594392 hasAuthorship W2254594392A5031781832 @default.
• W2254594392 hasAuthorship W2254594392A5037357027 @default.
• W2254594392 hasAuthorship W2254594392A5039187516 @default.
• W2254594392 hasAuthorship W2254594392A5039195753 @default.
• W2254594392 hasAuthorship W2254594392A5045032869 @default.
• W2254594392 hasAuthorship W2254594392A5047177507 @default.
• W2254594392 hasAuthorship W2254594392A5049243227 @default.
• W2254594392 hasAuthorship W2254594392A5049839632 @default.
• W2254594392 hasAuthorship W2254594392A5062978331 @default.
• W2254594392 hasAuthorship W2254594392A5069777765 @default.
• W2254594392 hasAuthorship W2254594392A5071577704 @default.
• W2254594392 hasAuthorship W2254594392A5072308451 @default.
• W2254594392 hasAuthorship W2254594392A5072582710 @default.
• W2254594392 hasAuthorship W2254594392A5075566772 @default.
• W2254594392 hasConcept C126322002 @default.
• W2254594392 hasConcept C143998085 @default.
• W2254594392 hasConcept C181199279 @default.
• W2254594392 hasConcept C184235292 @default.

• next